Ray P K, Bandyopadhyay S, Dohadwala M, Canchanapan P, Mobini J
Cancer Immunol Immunother. 1984;18(1):29-34. doi: 10.1007/BF00205396.
This report confirms our previous observation that IV inoculation of purified protein A causes regression of rat mammary adenocarcinomas. In treated tumors, we have obtained histological evidence of changes indicating tumor cell destruction. Protein A treatment does not cause reduction in the body weight or organ weights of rats; nor does it cause any decrease in activity of the enzymes of the microsomal mixed function oxidase system in the liver. Protein A stimulates peripheral white cell counts in normal rats, but not in tumor-bearing rats. We found that protein A infusion reduced (P less than 0.0005) the level of circulating plasma immune complex concentration. A homing study with 125I-labeled protein A indicated that liver, spleen, and kidney tissues are the major sites of protein A accumulation. Therefore, protein A seemed to exert its antitumor effects without causing any generalized toxicity to the system. It is postulated that the action of protein A may be related to its ability to cause a drastic reduction in circulating plasma immune complex concentration, thus potentiating the immune reactivity of the host observed earlier.
本报告证实了我们之前的观察结果,即静脉注射纯化的蛋白A可使大鼠乳腺腺癌消退。在接受治疗的肿瘤中,我们获得了表明肿瘤细胞破坏的组织学变化证据。蛋白A治疗不会导致大鼠体重或器官重量减轻;也不会导致肝脏微粒体混合功能氧化酶系统的酶活性降低。蛋白A可刺激正常大鼠的外周白细胞计数,但对荷瘤大鼠无此作用。我们发现,输注蛋白A可降低(P<0.0005)循环血浆免疫复合物浓度水平。一项用125I标记蛋白A的归巢研究表明,肝脏、脾脏和肾脏组织是蛋白A积累的主要部位。因此,蛋白A似乎在不对系统造成任何全身性毒性的情况下发挥其抗肿瘤作用。据推测,蛋白A的作用可能与其大幅降低循环血浆免疫复合物浓度的能力有关,从而增强了宿主先前观察到的免疫反应性。